Dyslipidemia: Epidemiology Report and Forecast to 2035

Powered by

All the vital news, analysis, and commentary curated by our industry experts.

Dyslipidemia is a medical condition characterized by abnormal lipid levels in the bloodstream, and includes the imbalance of cholesterol, low-density lipoprotein cholesterol (LDL-C), triglycerides (TG), and high-density lipoprotein cholesterol (HDL-C) (Pappan, Awosika and Rehman, 2024; Roland, 2026). Dyslipidemia increases the risk of cardiovascular disease (CVD), and has been associated with multiple diseases, including type 2 diabetes (T2D), neurodegenerative diseases, and cancer (Zhu et al., 2024). Dyslipidemia is classified into primary dyslipidemia and secondary dyslipidemia. Primary dyslipidemia refers to dyslipidemia caused by genetic mutations that affect lipid metabolism, such as familial hypercholesterolemia (FH), familial hypertriglyceridemia, familial combined hyperlipidemia, and familial dysbetalipoproteinemia. Secondary dyslipidemia is caused by lifestyle factors and disease conditions that alter lipid levels. Examples of causative factors include smoking, obesity, hypothyroidism, and chronic kidney disease (CKD) (Pappan, Awosika and Rehman, 2024; Roland, 2026).

Risk factors of dyslipidemia include having a diet that is high in saturated fatty acids (SFA) or trans fatty acids (TFA) and low in soluble fiber, excessive alcohol use, tobacco use, low physical activity, hypothyroidism, and drug use (Liu and Peng, 2022; Mosteoru, Gaiţӑ and Gaiţӑ, 2023; Nordestgaard et al., 2013; Pappan, Awosika and Rehman, 2024; Park and Lee, 2025; Schoeneck and Iggman, 2021; Sousa et al., 2024; Tziomalos et al., 2011; Xu et al., 2025; Yanai and Yoshida, 2021). CVD, including coronary artery disease (CAD) and stroke, is a common comorbidity of dyslipidemia. Additionally, T2D, obesity, CKD, and liver disease act both as risk factors and comorbidities of dyslipidemia (Ahmmed et al., 2021; Allara et al., 2019; Charlat et al., 2025; Chelioti et al., 2021; Hedayatnia et al., 2020; Klop, Elte and Cabezas, 2013; Li et al., 2025; Zheng et al., 2024).

Scope

The Dyslipidemia: Epidemiology Report and Forecast Model provide an overview of the risk factors, comorbidities, and global trends of dyslipidemia in the seven major markets (7MM: US, France, Germany, Italy, Spain, UK, and Japan).

The report includes a 10-year epidemiology forecast for the total and diagnosed prevalent cases of dyslipidemia segmented by age (0–19 years, 20–64 years, 65 years and older) and sex, as well as the total prevalent cases of elevated LDL-C (≥130mg/dL), high TG (≥200mg/dL), very high TG (≥500mg/dL), and low HDL-C (<40mg/dL [men, women 0–19 years], <50mg/dL [women 20 years and older]), segmented by age. Additionally, the model also provides total and diagnosed prevalent cases of heterozygous FH segmented by age and sex, and total and diagnosed prevalence of mixed dyslipidemia, homozygous FH, FH, and elevated lipoprotein(a) (≥50mg/dL) for men and women of all ages.

Reasons to Buy

The Dyslipidemia Epidemiology series will allow you to:

Develop business strategies by understanding the trends shaping and driving the global dyslipidemia markets.

Quantify patient populations in the global dyslipidemia markets to improve product design, pricing, and launch plans.

Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for dyslipidemia therapeutics in each of the markets covered.

Understand magnitude of the dyslipidemia population by age, and sex.

Table of Contents

Table of Contents

List of Tables

List of Figures

1 Executive Summary

1.1 Catalyst

1.2 Related reports

1.3 Upcoming reports

2 Epidemiology

2.1 Disease background

2.2 Risk factors and comorbidities

2.3 Global and historical trends

2.4 7MM forecast methodology

2.4.1 Sources

2.4.2 Forecast assumptions and methods

2.4.3 Forecast assumptions and methods: total and diagnosed prevalent cases of dyslipidemia

2.4.4 Forecast assumptions and methods: total prevalent cases of elevated low-density lipoprotein cholesterol

2.4.5 Forecast assumptions and methods: total prevalent cases of high triglycerides and very high triglycerides

2.4.6 Forecast assumptions and methods: total prevalent cases of low high-density lipoprotein cholesterol

2.4.7 Forecast assumptions and methods: total and diagnosed prevalent cases of mixed dyslipidemias

2.4.8 Forecast assumptions and methods: total and diagnosed prevalent cases of familial hypercholesterolemia

2.4.9 Forecast assumptions and methods: total and diagnosed prevalent cases of elevated lipoprotein(a)

2.5 Epidemiological forecast for dyslipidemia (2025–35)

2.5.1 Total prevalent cases of dyslipidemia

2.5.2 Age-specific total prevalent cases of dyslipidemia

2.5.3 Sex-specific total prevalent cases of dyslipidemia

2.5.4 Diagnosed prevalent cases of dyslipidemia

2.5.5 Age-specific diagnosed prevalent cases of dyslipidemia

2.5.6 Sex-specific diagnosed prevalent cases of dyslipidemia

2.5.7 Total prevalent cases of elevated low-density lipoprotein cholesterol

2.5.8 Total prevalent cases of high and very high triglycerides

2.5.9 Total prevalent cases of low high-density lipoprotein cholesterol

2.5.10 Total and diagnosed prevalent cases of mixed dyslipidemia

2.5.11 Total and diagnosed prevalent cases of familial hypercholesterolemia

2.5.12 Total and diagnosed prevalent cases of elevated lipoprotein(a)

2.6 Discussion

2.6.1 Epidemiological forecast insight

2.6.2 Limitations of the analysis

2.6.3 Strengths of the analysis

3 Appendix

3.1 Bibliography

3.2 About the Authors

3.2.1 Epidemiologist

3.2.2 Reviewers

3.2.3 Vice President of Disease Intelligence and Epidemiology

3.2.4 Global Head of Pharma Research, Analysis, and Competitive Intelligence

About GlobalData

Contact Us

Table

Table 1: Summary of newly added data types

Table 2: Summary of updated data types

Table 3: Risk factors and comorbidities for Dyslipidemia

Figures

Figure 1: 7MM, total prevalent cases of dyslipidemia, men and women, N, all ages, 2025 and 2035

Figure 2: 7MM, diagnosed prevalent cases of dyslipidemia, men and women, N, all ages, 2025 and 2035

Figure 3: 7MM, total prevalence of dyslipidemia, men and women, %, all ages, 2015–35

Figure 4: 7MM, diagnosed prevalence of dyslipidemia, men and women, %, all ages, 2015–35

Figure 5: 7MM, sources used to forecast the total prevalent cases of dyslipidemia

Figure 6: 7MM, sources used to forecast the diagnosed prevalent cases of dyslipidemia

Figure 7: 7MM, sources used and not used to forecast the total prevalent cases of elevated LDL-C

Figure 8: 7MM, sources used and not used to forecast the total prevalent cases of high and very high TG

Figure 9: 7MM, sources used and not used to forecast the total prevalent cases of low HDL-C

Figure 10: 7MM, sources used and not used to forecast the total and diagnosed prevalent cases of mixed dyslipidemia

Figure 11: 7MM, sources used and not used to forecast the total and diagnosed prevalent cases of FH

Figure 12: 7MM, sources used and not used to forecast the total and diagnosed prevalent cases of elevated lipoprotein(a)

igure 13: 7MM, total prevalent cases of dyslipidemia, N, men and women, all ages, 2025

Figure 14: 7MM, total prevalent cases of dyslipidemia by age, N, men and women, 2025

Figure 15: 7MM, total prevalent cases of dyslipidemia by sex, N, all ages, 2025

Figure 16: 7MM, diagnosed prevalent cases of dyslipidemia, N, men and women, all ages, 2025

Figure 17: 7MM, diagnosed prevalent cases of dyslipidemia by age, N, men and women, 2025

Figure 18: 7MM, diagnosed prevalent cases of dyslipidemia by sex, N, all ages, 2025

Figure 19: 7MM, total prevalent cases of elevated LDL-C, N, men and women, all ages, 2025–35

Figure 20: 7MM, total prevalent cases of high TG, N, men and women, all ages, 2025–35

Figure 21: 7MM, total prevalent cases of very high TG, N, men and women, all ages, 2025–35

Figure 22: 7MM, total prevalent cases of low HDL-C, N, men and women, all ages, 2025–35

Figure 23: 7MM, total prevalent cases of mixed dyslipidemia, N, men and women, all ages, 2025

Figure 24: 7MM, diagnosed prevalent cases of mixed dyslipidemia, N, men and women, all ages, 2025

Figure 25: 7MM, total prevalent cases of FH, N, men and women, all ages, 2025

Figure 26: 7MM, diagnosed prevalent cases of FH, N, men and women, all ages, 2025

Figure 27: 7MM, total prevalent cases of elevated lipoprotein(a), N, men and women, all ages, 2025

Figure 28: 7MM, diagnosed prevalent cases of elevated lipoprotein(a), N, men and women, all ages, 2025

Dyslipidemia: Epidemiology Report and Forecast to 2035 standard reports
Currency USD
$9,995

Can be used by individual purchaser only

$29,985

Can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company


Undecided about purchasing this report?

Enquire Before Buying Download FREE Resources

Get in touch to find out about multi-purchase discounts

reportstore@globaldata.com
Tel +44 20 7947 2745

Sample Report

Dyslipidemia: Epidemiology Report and Forecast to 2035 was curated by the best experts in the industry and we are confident about its unique quality. However, we want you to make the most beneficial decision for your business, so we offer free sample pages to help you:

  • Assess the relevance of the report
  • Evaluate the quality of the report
  • Justify the cost

Download your copy of the sample report and make an informed decision about whether the full report will provide you with the insights and information you need.

Below is a sample report to understand what you are buying

See what our customers are saying
testimonial-image
testimonial-image
testimonial-image
testimonial-image
testimonial-image
testimonial-image
testimonial-image

“The GlobalData platform is our go-to tool for intelligence services. GlobalData provides an easy way to access comprehensive intelligence data around multiple sectors, which essentially makes it a one-for-all intelligence platform, for tendering and approaching customers.

GlobalData is very customer orientated, with a high degree of personalised services, which benefits everyday use. The highly detailed project intelligence and forecast reports can be utilised across multiple departments and workflow scopes, from operational to strategic level, and often support strategic decisions. GlobalData Analytics and visualisation solutions has contributed positively when preparing management presentations and strategic papers.”

Business Intelligence & Marketing Manager, SAL Heavy Lift

“COVID-19 has caused significant interference to our business and the COVID-19 intelligence from GlobalData has helped us reach better decisions around strategy. These two highlights have helped enormously to understand the projections into the future concerning our business units, we also utilise the project database to source new projects for Liebherr-Werk to use as an additional source to pitch for new business.”

Market Analyst & Management, Liebherr-Werk

Your daily news has saved me a lot of time and keeps me up-to-date with what is happening in the market, I like that you almost always have a link to the source origin. We also use your market data in our Strategic Business Process to support our business decisions. By having everything in one place on the Intelligence Center it has saved me a lot of time versus looking on different sources, the alert function also helps with this.

Head of Key Accounts, Saab AB

Having used several other market research companies, I find that GlobalData manages to provide that ‘difficult-to-get’ market data that others can’t, as well as very diverse and complete consumer surveys.

Marketing Intelligence Manager, Portugal Foods

Our experience with GlobalData has been very good, from the platform itself to the people. I find that the analysts and the account team have a high level of customer focus and responsiveness and therefore I can always rely on. The platform is more holistic than other providers. It is convenient and almost like a one stop shop. The pricing suite is highly competitive and value for our organisation.

I like reports that inform new segments such as the analysis on generation Z, millennials, the impact of COVID 19 to our banking customers and their new channel habits. Secondly the specialist insight on affluent sector significantly increases our understanding about this group of customers. The combination of those give us depth and breadth of the evolving market.

I’m in the business of answering and helping people make decisions so with the intelligence center I can do that, effectively and efficiently. I can share quickly key insights that answer and satisfy our country stakeholders by giving them many quality studies and primary research about competitive landscape beyond the outlook of our bank. It helps me be seen as an advisory partner and that makes a big difference. A big benefit of our subscription is that no one holds the whole data and because it allows so many people, so many different parts of our organisation have access, it enables all teams to have the same level of knowledge and decision support.

Head of Customer Insight and Research, Standard Chartered

“I know that I can always rely on Globaldata’s work when I’m searching for the right consumer and market insights. I use Globaldata insights to understand the changing market & consumer landscape and help create better taste & wellbeing solutions for our customers in food, beverage and healthcare industries.

Globaldata has the right data and the reports are of very high quality compared to your competitors. Globaldata not only has overall market sizes & consumer insights on food & beverages but also provides insights at the ingredient & flavour level. That is key for B2B companies like Givaudan. This way we understand our customers’ business and also gain insight to our unique industry”

Head of Consumer Sensory Insights, Givaudan

GlobalData provides a great range of information and reports on various sectors that is highly relevant, timely, easy to access and utilise.  The reports and data dashboards help engagement with clients; they provide valuable industry and market insights that can enrich client conversations and can help in the shaping of value propositions. Moreover, using GlobalData products has helped increase my knowledge of the finance sector, the players within it, and the general threats and opportunities.

I find the consumer surveys that are carried out to be extremely beneficial and not something I have seen anywhere else. They provided an insightful view of why and which consumers take (or don’t) particular financial products. This can help shape conversations with clients to ensure they make the right strategic decisions for their business.

One of the challenges I have found is that data in the payments space is often piecemeal. With GD all of the data I need is in one place, but it also comes with additional market reports that provide useful extra context and information. Having the ability to set-up alerts on relevant movements in the industry, be it competitors or customers, and have them emailed directly to me, ensures I get early sight of industry activity and don’t have to search for news.

Senior Account Manager, TSYS
Go even deeper with GlobalData Intelligence Center

Every Company Report we produce is powered by the GlobalData Intelligence Center.

Subscribing to our intelligence platform means you can monitor developments at Dyslipidemia: Epidemiology Report and Forecast to 2035 in real time.

  • Access a live Dyslipidemia: Epidemiology Report and Forecast to 2035 dashboard for 12 months, with up-to-the-minute insights.
  • Fuel your decision making with real-time deal coverage and media activity.
  • Turn insights on financials, deals, products and pipelines into powerful agents of commercial advantage.